Abstract
Purpose :
Pleckstrin homology domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) is linked to various pathological
states. However, whether PHLPP2 mediates diabetic retinopathy is unaddressed. This work explored the biological
function of PHLPP2 in modulating high glucose (HG)-elicited damage of retinal ganglion cells (RGCs), an in vitro model
for studying diabetic retinopathy.
Methods :
Mouse RGCs were treated with HG to establish a cell model. PHLPP2 was silenced by transfecting specific shRNAs
targeting PHLPP2. RT-qPCR, immunoblotting, CCK-8 assay, flow cytometry, TUNEL assay, and ELISA were carried out.
Results :
Significant increases in PHLPP2 levels were observed in cultured RGCs exposed to HG. The severe damages evoked
by HG to RGCs were remarkably weakened in PHLPP2-silenced RGCs, including improved cell survival, attenuated cell
apoptosis, repressed oxidative stress, and prohibited proinflammatory response. The silencing of PHLPP2 strengthened
the activation of Nrf2 in HG-treated RGCs via modulation of the Akt–GSK–3β axis. Interruption of the Akt–GSK–3β axis
reversed PHLPP2-silencing-elicited Nrf2 activation. The protective effects of PHLPP2 silencing on HG-induced injury of
RGCs were diminished by Nrf2 inhibition.
Conclusions :
The loss of PHLPP2 was beneficial for HG-injured RGCs through the effect on the Akt–GSK–3β–Nrf2 pathway.
This work suggests a possible role of PHLPP2 in diabetic retinopathy.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.